Get started

Volumespreadanalysis

$AGRX Next Target 2.50-2.75 and higherAgile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
ALong
by BADQOMOCAWGOWLD
JICPT| BTC is probably heading to $15500 for another range move!Hello everyone. There is a lot of news circulating in the crypto market, from the sudden crash of Terra luna to the 3AC liquidation. It seems buyers are reluctant to get in after 70%+ drop of BTC based on the volume market in the chart. Where could it go? It could be on the way to test $15500 by measured move. In the short term, I don't see any rebound happen soon as there is no huge volume and reversal candle patterns formed. What do you think? Give me a like if you're with me.
BITFINEX:BTCUSDShort
by JICPT
BTC Update - Volume analysis and 3 ScenariosOn the 4h chart we can establish that we are in neutral territory. Oscilators are low, MAs are neutral and we are blocked in a VPVR range that has a low of $20.4k and a high of $21160. The last 4 candles have a low ATR and therefore we do not have much room to trade. Due to the fact that the candle -2 was a doji and it was engulfed we can assume with around 80% certainty that we will go for the POC level($21160) at least for a retest. We also have two demand zones on the 4h tf -Low demand zone is situated between 19.1k and 19.5k -High demand zone between 17.9k and 18.2k The positives: Since our last low @ 17.4k we have firned a V shape reversal that has since stayed in an uptrend(Higher Highs , Higher Lows), we do not necessarily need to look for shorts. Scenarios: 1 - Test POC then back to the orderblock formed by the engulfed doji then break the previous high. 2 - Test POC then back out of the range to around 0.38 Fib(0.618 symmetry) then back in the range with some good volume 3 - Head down to 0.5 Fib / Breaker zone and wick down into the low supply/0.618 Fib Volume analysis: Ever since the V shape reversal we have seen very little and inconsistent institutional volume, and if we look at the way the volume candles are plotted we can see that sellers are more organized and consistent. The volume analysis favors scenario 3 for now but it can be invalidated IF we get a market opening spike. Remember - Institutional(High Volume) is ment to take the price to a certain level. Stay tuned for more updates!
BINANCE:BTCUSD.P
by SublimeTraders
$QOMUSDT Shiba Predator0xa71d0588EAf47f12B13cF8eC750430d21DF04974 SHIBA FLIPPED DOGE NOW WE FLIP SHIBA You are the Team Yes, we are all QOM and we are all the team. For this to work, “a thousand flowers must blossom” and we all must do our part Just like Shiba, there are no team tokens If you want to do something then do it, if someone asks for a hand out you can tell them that Shiba never paid for a thing. Trust The Process Flipping Shiba will take Diamond Hands. Don’t be short-sighted with QOM, there is a long road ahead of us. HODL Ask not what QOM can do for you, ask what you can do for QOM QOM started this with a contract deploy and a group, but it is really up to you (QOM also) to see what you can add. Work for you meal, add what you can and tell your frens. This is an army. It is new and small, but that also means we have advantage.
QLong
by BADQOMOCAWGOWLD
$BKSY Next Target PTs 4-4.75 Long term PT 29 and higherBlackSky Technologies Inc. (NYSE: BKSY) was awarded a basic order agreement from the Joint Artificial Intelligence Center (JAIC) to create and optimize data sets for use in DoD AI models and applications. The JAIC agreement has a ceiling value of $241 million over five years. BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operations of satellite and ground systems to commercial and government customers worldwide. The company processes a range of observations from its constellation, as well as various space, internet-of-things, and terrestrial based sensors and data feeds. Its products are used in government defense and intelligence; commercial, construction, and industrial; and catastrophe, climate, and environment applications. The company was incorporated in 2014 and is headquartered in Herndon, Virginia.
NYSE:BKSYLong
by BADQOMOCAWGOWLD
Showcase: Trading the e-mini Dow Jones (YM) 22-06-201. Did a long trade (paper trading) on e-mini Dow Jones. 2. Reason for the long trade: a) Price do a higher lower; a UT bar appears but the next bar overtake the UT. b) Volume is supporting the upward move. c) Strong support level at 29910 range. 3. Trade entered with SL @ 50pts and TP @ 75pts; as price move upwards with unrealised profit, the SL is revised upwards to minimise the losses and eventually lock-in the profit. 4. Price eventually do a pullback after breaking the recent Resistance (29966 range); our SL got hit and we exited with a realised profit of 24pts. 5. Price may move upwards from hereon; it is OK to exit with a small profit rather than be ambitious.
CBOT_MINI:YM1!Long
by mdalifalwi
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
$AERC entry PTs 16-17.70 Next Target PT 28 and higher Long term AeroClean Technologies, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. It provides Purgo, an air sanitization product for indoor spaces; and Purgo Lift that provides air purification solution for elevators and other wall-mount applications. The company was formerly known as AeroClean Technologies, LLC. AeroClean Technologies, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
ALong
by BADQOMOCAWGOWLD
$AUVI Next Target PT 4.50 and higher Long term PT 35 and higherApplied UV, Inc., through its subsidiaries, develops, acquires, and commercializes technology that addresses air purification and infection control in the healthcare, hospitality, commercial, municipal, and residential markets in the United States, Canada, and Europe. It operates through Disinfection and Hospitality segments. The company offers science-based solutions and products in air purification under the Airocide brand; and disinfection of hard surfaces under the Lumicide brand. It also manufactures and supplies fine decorative framed mirrors, framed arts, and bathroom vanities. The company was incorporated in 2019 and is headquartered in Mount Vernon, New York.
ALong
by BADQOMOCAWGOWLD
1
$SIDU Long term PT 59 and higher Timeline: Jan 2023Sidus Space is a Teammate on NASA’s $3.5 Billion Exploration Extravehicular Activity Services Contract Sidus Space, Inc., a space-as-a-service company, engages in the design, manufacture, launch, and data collection of commercial satellite worldwide. Its services include satellite manufacturing; precision manufacturing, assembly, and test; low earth orbit microsatellite; payload integrations; launch and support services; space-based data services and analytics; precision computer numerical control machining and fabrication; Swiss screw machining; wire cable harness fabrication; 3D composite and metal printing; and satellite deployment and microgravity testing and research services, as well as services related to electrical and electronic assemblies. The company also offers hardware solutions consisting of an external flight test platform to develop, test, and fly experiments, as well as delivers hardware, materials, and advanced electronics on the international space station; and space station integrated kinetic launcher for orbital payload systems. It serves commercial space, aerospace, defense, underwater marine, and other commercial and government customers. The company was founded in 2014 and is headquartered in Merritt Island, Florida. Sidus Space, Inc. is a subsidiary of Craig Technical Consulting, Inc.
NASDAQ:SIDULong
by BADQOMOCAWGOWLD
1
$BTTX entry PTs 1.30-1.40 Long term PT 17-50 and higherBetter Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
BLong
by BADQOMOCAWGOWLD
$QNGY entry PTs .40-.45 Long term PT 40 and higher Quanergy Systems, Inc. develops and markets light detection and ranging (LiDAR) solutions for automotive and IoT applications. The company offers M1 LiDAR sensor for mid-long range industrial measurement applications; M1 Edge 2D LiDAR sensor that enables reliable collision avoidance and smart navigation; M8 LiDAR sensor, which provides 3D perception using multiple eye-safe laser beams and time-of-flight measurement technology; MQ-8 LiDAR sensor for flow management applications; M8-Prime 3D LiDAR sensor that provides industry-leading pinpoint accuracy and captures for industrial and mapping applications; S3 solid state LiDAR sensor; QORTEX DTC, a 3D computer perception software; and QORTEX people counter enables the development of accurate and innovative people counting and queue management applications. Its products are used in various applications, such as mapping, security, smart city and smart spaces, industrial automation, and transportation applications. The company was founded in 2012 and is headquartered in Sunnyvale, California.
QLong
by BADQOMOCAWGOWLD
LaVinci's 30-Day PlanUnfortunately, we cannot predict the future. We can, however, predict the immediate future as a function of our free will in conflict with the universe around us. In anticipation of BTCUSD dropping to the 22,000 area, as a bearish harmonic extension distributes' itself, LaVinci has devised a plan to accumulate BTCUSD over the course of the next month. The goal is to avert risk while simultaneously reap rewards by scaling into multiple LONG positions over the course of the above mentioned time period (30 days). Stop-Losses are also devised in the plan to scale out and liquidate the long positions in the event that the current structure fails to react accordingly. Take-Profits aren't being taken into account just yet, for the anticipated time that this position will be held is going to be between 70-90 days. Please follow & critique, as critical feedback is strongly encouraged! Thanks, LaVinci
BITSTAMP:BTCUSDLong
by LaVinci
1
One of Most Bullish Days for Ethereum: $750 billion Shorts As per liquidation information on the digital currency market given by IP TRADE, Ethereum saw one of the greatest liquidation volumes over the most recent couple of months, on the off chance that not years, with nearly $800 Billion worth of orders being vanished from the market. Such a huge liquidation volume showed up after Ethereum skipped off the helpline at $1,715 and acquired around 4% of its worth. The crush has undoubtedly seemed due to dealers' and financial backers' conviction that the second greatest digital money available will dip under $1,700 and hurry to the following help at around $1,500.
BITSTAMP:ETHUSDLong
by IPatrice
4